Drug Profile

Lexaptepid pegol

Alternative Names: NOX-H94

Latest Information Update: 01 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NOXXON Pharma AG
Developer TME Pharma
Class Antianaemics; Oligonucleotides; Polyethylene glycols
Mechanism of Action Hepcidin inhibitors; Interleukin 6 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Anaemia

Highest Development Phases

Discontinued Anaemia

Most Recent Events

18 Oct 2018 Discontinued - Phase-I for Anaemia (In volunteers) in Netherlands (IV)
18 Oct 2018 Discontinued - Phase-I for Anaemia (In volunteers) in United Kingdom (SC)
18 Oct 2018 Discontinued - Phase-I/II for Anaemia in Italy, Germany, United Kingdom (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com